How Oral TYK2 Inhibition Is Showing Up in Real Decisions

Once you move past mechanism, the question becomes simpler and harder at the same time: where does this actually fit? 

In this conversation, Benjamin Lockshin, MD, and Michael Cameron, MD, walk through how they’re using TYK2 inhibition in practice—who gets it, when they start, and where it sits alongside biologics and other systemic options. 

For some patients, it’s a first-line consideration. Those with milder joint involvement alongside psoriasis. Patients who prefer to start with an oral option, or those who don’t quite fit the thresholds that typically push toward biologics. 

For others, it’s additive—layered onto a biologic in partial responders, used in harder-to-treat areas like palmoplantar disease or in patients where weight may affect response.

Running through the discussion is a familiar nuance: when to manage independently and when to refer, how much to act on early or vague joint symptoms, and how to balance simplicity with a growing number of treatment choices. 

Less about defining a fixed place in the algorithm, more about understanding where it becomes useful across different types of patients.